Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Seifried

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Zeitschrift Fur Kardiologie|January 1, 1993
[Laboratory monitoring of thrombolytic therapy in clinical practice and research]M Grünewald, E Seifried
Vox Sanguinis|January 12, 2010
Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?H Schrezenmeier, E Seifried
Zentralblatt Fur Chirurgie|January 1, 1995
[Costs of safety of blood and blood products]E Seifried, G Soedel
Arzneimittel-Forschung|November 1, 1989
Current developments in thrombolytic therapy using novel plasminogen activatorsE Seifried, P Tanswell
Thrombosis and Haemostasis|October 28, 1987
Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parametersE Seifried, P Tanswell
Infusionstherapie Und Transfusionsmedizin|April 1, 1993
[Therapy of autoimmune thrombocytopenia in adults]E Gunsilius, E Seifried
Transfusion Medicine (Oxford, England)|September 11, 2002
The German experience with NATW K Roth, E Seifried
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 14, 2001
Yield and future issues of nucleic acid testingW K Roth, E Seifried
Transfusion|June 16, 2001
Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?W K Roth, E Seifried
Thrombosis and Haemostasis|November 30, 1990
In vitro effects of urokinase--prevention by different inhibitorsM D Oethinger, E Seifried
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Zeitschrift Fur Kardiologie|January 1, 1993
[Laboratory monitoring of thrombolytic therapy in clinical practice and research]M Grünewald, E Seifried
Vox Sanguinis|January 12, 2010
Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?H Schrezenmeier, E Seifried
Zentralblatt Fur Chirurgie|January 1, 1995
[Costs of safety of blood and blood products]E Seifried, G Soedel
Arzneimittel-Forschung|November 1, 1989
Current developments in thrombolytic therapy using novel plasminogen activatorsE Seifried, P Tanswell
Thrombosis and Haemostasis|October 28, 1987
Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parametersE Seifried, P Tanswell
Infusionstherapie Und Transfusionsmedizin|April 1, 1993
[Therapy of autoimmune thrombocytopenia in adults]E Gunsilius, E Seifried
Transfusion Medicine (Oxford, England)|September 11, 2002
The German experience with NATW K Roth, E Seifried
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 14, 2001
Yield and future issues of nucleic acid testingW K Roth, E Seifried
Transfusion|June 16, 2001
Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?W K Roth, E Seifried
Thrombosis and Haemostasis|November 30, 1990
In vitro effects of urokinase--prevention by different inhibitorsM D Oethinger, E Seifried
Pageof 23